
Dr. Michael Jeng, MD
Palo Alto, CA
Affiliated with a Castle Connolly Top Hospital
Who is Dr. Jeng, Pediatric Hematologist-Oncologist in Palo Alto, CA?
Dr. Michael Jeng, MD is a Pediatric Hematologist-Oncologist, who primarily practices in Palo Alto, CA. He is board certified. Dr. Jeng graduated from Case Western Reserve University School of Medicine and completed his residency at Ann & Robert H. Lurie Children's Hospital of Chicago. Dr. Jeng is fluent in English and Chinese, and is currently seeing new patients. Dr. Jeng’s practice accepts Medicare, Aetna, Cigna and other major insurance plans. To book an appointment or to confirm insurance options, please call Dr. Jeng’s office at (650) 497-8000.
What are Areas of Expertise for Dr. Jeng?
Dr. Michael Jeng, MD is a highly-rated, board-certified Pediatric Hematologist-Oncologist known for expertly diagnosing, treating, and managing a wide array of related conditions and procedures. Utilizing the latest medical advancements and evidence-based practices, Dr. Jeng empowers patients to confidently navigate their health journey, specializing in Pediatric Hematology, and comprehensive wellness support. Serving the Palo Alto, CA community, Dr. Jeng is dedicated to enhancing lives through expert, patient-centered care.
Where did Dr. Jeng go to medical school and complete their residency?
Fellowship: Children's Hospital Oakland, Oakland, CA | Children's Hospital Oakland CA
Residency: Ann & Robert H. Lurie Children's Hospital of Chicago
Medical School: Case Western Reserve University School of Medicine
Is Dr. Jeng board certified as a Pediatric Hematologist-Oncologist?
Yes, Dr. Michael Jeng, MD is board certified by the American Board of Dermatology , American Board of Dermatology since 2000
What languages does Dr. Jeng speak?
Dr. Jeng and their clinical team can communicate with patients in the following languages:
Chinese
English
What conditions does a Pediatric Hematologist-Oncologist like Dr. Jeng typically treat?
As a Pediatric Hematologist-Oncologist, Dr. Jeng diagnoses, treats, and manages a wide range of conditions. This condition information is derived from anonymized insurance claims and highlights the medical conditions most commonly treated by Dr. Jeng. It provides insight into the doctor’s areas of experience and expertise based on real-world patient encounters from the past two years, updated quarterly. Learn more about our claims-based healthcare methodology.
Also known as:
- Cancer Chemotherapy
- Chemo treatment
- Oncology chemotherapy
- Cancer drug therapy
ICD-10 Codes:
- Z5111: Encounter for antineoplastic chemotherapy
Also known as:
- Langerhans Cell Histiocytosis
- Langerhans cell histiocytosis
- Langerhans Cell Histiocytosis Treatment (PDQ)
- LCH
- Unifocal LCH
ICD-10 Codes:
- C966: Unifocal Langerhans-cell histiocytosis
Also known as:
- Peripheral Vascular Malformation
- Birth Defects
- Blood Vessel Birth Defect
- Vascular Anomaly
- Limb Vascular Defect
ICD-10 Codes:
- Q279: Congenital malformation of peripheral vascular system, unspecified
Also known as:
- Iron Deficiency Anemia
- Anemia
- Iron
- Anemia from Iron Lack
- Low Iron Anemia
- Sideropenic Anemia
ICD-10 Codes:
- D509: Iron deficiency anemia, unspecified
- D508: Other iron deficiency anemias
Also known as:
- Acute Lymphocytic Leukemia in Remission
- Acute Lymphocytic Leukemia
- ALL Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Childhood Leukemia in Remission
ICD-10 Codes:
- C9101: Acute lymphoblastic leukemia, in remission
What procedures does a Pediatric Hematologist-Oncologist like Dr. Jeng typically perform?
As a Pediatric Hematologist-Oncologist, procedures performed by Dr. Michael Jeng may include:
- 3D Conformal Radiotherapy
- Adaptive Radiation Therapy (ART)
- Adrenalectomy
- Blood Thinning Therapy / Anticoagulation
- Blood Transfusion Consultation
- Blood Transfusion Follow Up
- Bone Excision
- Bone Grafting
Please contact Dr. Jeng's office directly to confirm care for your specific procedure, for more information, or to schedule a consultation.
Does Dr. Jeng accept my insurance?
Dr. Jeng accepts most major insurance plans. Important: Please call our office at (650) 497-8000 before your appointment to verify that your specific plan and network are accepted.
What insurance plans does Dr. Jeng accept in Palo Alto, CA?
Dr. Jeng in Palo Alto, CA accepts plans from many carriers. While this list is updated regularly, it is not a guarantee of coverage.
Top Insurances
All Other Third Party
Blue Shield of California
California Water Service Group
CVS Health (formerly Aetna)
Molina Healthcare
Other Health Care Provider
Santa Cruz County
State of California
UnitedHealth Group
Unknown
View All Insurances
Where is Dr. Jeng's office located?
Recognitions
Awards
Dr. Marion Koerper Award for Medical Excellence, Hemophilia Foundation
LeBonheur Children's Hospital
St. Jude Teaching Award
Publications
Oxandrolone for the treatment of bone marrow failure in Fanconi anemia.
, 2014
Immune Thrombocytopenia in Children Less Than 1 Year of Age
, 2013
Clofarabine salvage therapy for refractory high-risk langerhans cell histiocytosis.
, 2013
An exploratory epidemiological study of Langerhans cell histiocytosis
, 2012
Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia
, 2012
Estimation of liver T*2 in transfusion
, 2012
Dissemited Intravascular Coagulation Due to IgM-Mediated Autoimmune Hemolytic Anemia
, 2011
Diffuse Infantile Hepatic Hemangiomas
, 2011
The role of vanin-1 and oxidative stress
, 2011
Effect of chronic red cell transfusion therapy on vasculopathies
, 2011
Effects of a 6-Week, Individualized
, 2010
Adherence to Study Medication and Visits: Data From the BABY HUG Trial
, 2010
Fusion of PDGFRB to two distinct loci at 3p21
, 2010
Monthly recombint tissue plasminogen activator administration to implantable central venous
, 2009
Neotal Alloimmune Thrombocytopenia
, 2009
Idiopathic neutropenia of childhood is associated with Fas/FasL expression
, 2008
Clofarabine in refractory Langerhans cell histiocytosis
, 2008
Neotal heparin overdose-a multidiscipliry team approach to medication error prevention.
, 2008
Relative response of patients with myelodysplastic syndromes
, 2008
Precursor B-Cell acute lymphoblastic leukemia presenting with hemophagocytic lymphohistiocytosis
, 2008
Gene expression and pathway alysis of immune thrombocytopenic purpura
, 2008
Cold agglutinin syndrome in pediatric liver transplant recipients
, 2007
Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02)
, 2007
Prospective evaluation of patient
, 2007
Darbepoetin alfa and ferric glucote ameliorate the anemia associated with recessive dystrophic
, 2006
Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle
, 2006
Gene expression profile of idiopathic thrombocytopenic purpura (ITP)
, 2006
Application of a geographic information system to explore associations between air pollution
, 2006
Granulocyte-macrophage colony stimulating factor
, 2005
Frequency of Fanconi anemia in Brazil and efficacy of screening for the FANCA 3788-3790del mutation
, 2005
Epstein-Barr virus-associated peripheral T-cell lymphoma
, 2005
Chronic transfusion therapy for children with sickle cell disease
, 2005
Hematologic problems in immigrants from Ssutheast Asia
, 2004
tural history of moderate aplastic anemia in children
, 2004
Cow's milk allergy in a patient with hyper-IgE syndrome
, 2004
Extranodal Rosai-Dorfman disease in children
, 2004
Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood.
, 2004
Effects of erythrocytapheresis transfusion on the viscoelasticity of sickle cell blood
, 2004
Identification of hemochromatosis gene polymorphisms
, 2003
Liver transplantation for acute Budd
, 2003
Resolution of chronic hepatic sequestration
, 2003
Pseudotumor cerebri in two adolescents with acquired aplastic anemia
, 2002
Summary of symposium: the future of stem cell transplantation for sickle cell disease.
Treatment of children with Langerhans cell histiocytosis with 2-chlorodeoxyadenosine
, 2002
Central venous catheter complications in sickle cell disease
, 2002
Itracozole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia
, 2001
Hydroquinone, a benzene metabolite
, 2000